PrP is a highly conserved, 35-kD brain glycoprotein essential for the transmission and pathogenesis of several neurodegenerative diseases, such as scrapie, bovine spongiform encephalopathy, Creutzfeldt-Jakob disease (CJD), and Gerstmann-StrausslerScheinker (GSS) disease (1) . Although the normal function of PrP remains unclear, the pathogenesis of prion diseases requires its expression (2) (3) (4) and is often accompanied by the accumulation in the brain of an abnormal isoform of PrP (termed PrP Sc ). Considerable evidence from biochemical, immunologic, pathologic, and genetic studies argues that PrP Sc is the major, if not only, component of the transmissible prion particle [reviewed in (1) ]. Furthermore, the data suggest that PrP Sc is able to propagate itself in the host by stimulating the conversion of normal cellular PrP (termed PrP C ) to PrP Sc , leading to its accumulation (5, 6) . Thus, although the exact mechanism of PrP C to PrP Sc conversion remains unknown, a foundation has been laid for the understanding of prion disease transmission, on which subsequent structural, biochemical, and cell biological studies can be based.
More enigmatic at the present time is our understanding of the biochemical and cell biological events that form the basis for the pathophysiological progression of neurodegeneration in prion diseases. The role of PrP Sc in the pathologic process leading to neuronal death is currently unclear. The observation of substantial neurodegeneration in the absence of PrP Sc accumulation in some cases of natural and experimental prion disease argues against its accumulation as the sole cause of pathology (7, 8) . Conversely, the time course of PrP Sc deposition in the brains of mice expressing low levels of PrP C does not correlate with the time course of neurodegeneration (9) , raising the possibility that PrP Sc is not directly toxic. This possibility is further supported by the demonstration that PrP Sc deposition fails to cause disease in brain tissue lacking PrP C (2) . Thus, although conversion of PrP C to PrP Sc appears to be central to transmission, other aspects of PrP expression, folding, and trafficking may feature in the pathophysiological mechanisms that ultimately cause disease.
Studies of PrP translocation at the endoplasmic reticulum (ER) membrane have revealed unusual features in its biogenesis. Whereas most glycoproteins are synthesized in a single orientation with respect to the membrane of the ER, PrP synthesized in cell-free translation systems can be found in more than one topologic form (10) (11) (12) (13) . One form appears to be fully translocated into the ER lumen and hence is termed the secretory form ( sec PrP). This topology is consistent with much of what is known about PrP C , which is on the cell surface, tethered to the membrane by a glycolipid anchor whose cleavage results in release from cells (14) . The remainder of the PrP made at the ER spans the membrane, with regions of the molecule exposed to the cytosol. However, the relation between these multiple topological forms of PrP and neurodegenerative disease has not been established, nor have transmembrane forms of PrP been previously detected in the brain.
Here, we used transgenic mice that express various mutations in PrP to examine the possible role of PrP topology in neurodegeneration. Our data indicate that a specific transmembrane form of PrP (termed Ctm PrP, see below) can confer severe neurodegeneration in mice with features typical of prion disease. Subsequent analysis of the human neurodegenerative disease caused by the A117V mutation [alanine (A) to valine (V) substitution at position 117] in PrP suggests that its basis lies in increased production of Ctm PrP at the ER membrane. These findings identify Ctm PrP as a key component in the pathway of neurodegeneration in a specific human disorder (GSS) and may have important implications for a broader range of neurodegenerative diseases.
PrP topology. The events of secretory and membrane protein biogenesis can be faithfully reconstituted and studied with cell-free translation systems containing ERderived microsomal membranes (15) . Topology of a protein can be assessed by determining whether any regions of the molecule are accessible to proteases added to the outside of the membrane vesicles. Full protection from exogenous protease indicates complete translocation into the ER lumen. Conversely, digestion of certain domains to yield discrete protease-protected fragments indicates a membrane-spanning topology, the exact orientation of which can be clarified by identification of the protected fragments with epitope-specific antibodies. This use of proteases as a probe of topology is distinctly different from the use of proteases as probes of protein conformation (for example, the protease resistance of PrP Sc ). Because the topology assay is carried out in the absence of detergent, the protection from protease is due to an intact membrane barrier. In contrast, the assay of PrP conformation by use of proteinase K (PK) is carried out in detergent solution, where only particular conformations of PrP, and not a membrane barrier, can protect it from digestion (16) .
Previous analyses of PrP topology have suggested that two distinct forms of PrP can be made at the ER: one that is fully translocated ( sec PrP) and one that is transmembrane (10) (11) (12) . Digestion of the transmembrane form with proteases added to the outside of the membrane yielded two fragments: One is COOH-terminal derived and glycosylated, and the other is NH 2 -terminal derived and unglycosylated. These data have been interpreted to indicate that transmembrane PrP chains span the membrane twice, with the NH 2 -and COOHtermini of the molecule in the ER lumen, protected from proteases added to the cytosolic side (10, 13) . However, the findings described below suggest that the NH 2 -and COOH-terminal fragments reflect the existence of two different transmembrane forms of PrP (Fig. 1A) . One form, termed C-trans transmembrane ( Ctm PrP), has the COOHterminus in the ER lumen with the NH 2 -terminus accessible to proteases in the cytosol. The other form, termed N-trans transmembrane ( Ntm PrP), has the NH 2 -terminus in the ER lumen with the COOHterminus accessible to proteases in the cytosol. Both transmembrane forms appear to span the membrane at the same hydrophobic stretch in PrP (roughly residues 110 to 135, previously termed TM1). For this reason, the proteolytic fragments derived from each transmembrane form share a common domain of PrP approximately from residues 105 to 140 (the residues immediately adjacent to the membrane-spanning domain are not digested by protease, perhaps because of steric hindrance by the membrane itself). Thus, both fragments share the epitope for the 3F4 monoclonal antibody (mAb) (to residues 109 to 112), whereas only the COOH-terminal fragment contains the epitope to the 13A5 mAb (to residues 138 to 141). These differences in antibody reactivity, glycosylation, and size allow the Ntm PrP and Ctm PrP fragments to be clearly distinguished.
Topology-altering mutations in PrP. Synthesis of both transmembrane forms of PrP is dependent on discrete sequences within the PrP coding region (12, 13, 17) . Two adjacent domains within PrP (Fig.  1B) , the hydrophobic, potentially membrane-spanning stretch from amino acids Ala 113 to Ser 135 (termed TM1) and the preceding hydrophilic domain [termed STE (for stop transfer effector) and presently narrowed to residues Lys 104 to Met 112 (18) ], appear to act in concert to generate both transmembrane forms of PrP. No helical structure in this region of PrP has been found by nuclear magnetic resonance studies of recombinant PrPs derived from Escherichia coli and studied in an aqueous environment (19) (20) (21) . Mutations, deletions, or insertions within these domains can alter the relative amounts of each topological form of PrP that is synthesized at the ER (12) . Given these complex and unusual features of PrP biogenesis and structure, it seemed plausible to think that its dysregulation may have dramatic consequences for the physiology of an organism.
To explore this hypothesis, we first identified four mutations within STE-TM1 (shown in Fig. 1C ) that greatly alter the ratio of the topological forms when assayed by cell-free translation. Two of these mutations (KH3 II and ⌬STE) were engineered into Syrian hamster PrP (SHaPrP), and the other two (AV3 and G123P) were put into MH2MPrP, a mouse-hamster chimera in which residues 94 to 188 are from hamster PrP (6) . We found that the species variation between SHaPrP and MH2MPrP (differing at eight residues) had little effect on topology (Fig. 1D) . However, a comparison of SHaPrP(KH3 II) with wild-type SHaPrP showed a marked increase (from ϳ10 to ϳ50%) in the relative amount of Ctm PrP synthesized, with a concomitant decrease in sec PrP (Fig. 1E) . The amount of Ntm PrP remained essentially unchanged. Similar results were obtained when MH2MPrP(AV3) was compared with MH2MPrP ( Fig. 1F) . In contrast, both SHaPrP(⌬STE) and MH2MPrP(G123P) were synthesized exclusively in the sec PrP form (Fig. 1 , E and F). These results, quantitated and summarized (Fig. 1G) , provided the basis for our subsequent examination of the effects of aberrant Ctm PrP synthesis in vivo. To do this, we expressed PrP transgenes encoding each of these mutations in mice that lacked the PrP gene [FVB/Prnp 0/0 (4)]. These mice were Fig. 2A) . In the F2 generation harboring the transgene (n ϭ 24), the average age of onset was 58 Ϯ 11 days, with the earliest development of symptoms at 41 days ( Transgenic mice expressing MH2MPrP-(AV3) at high levels also showed neurological signs of illness and death within 2 months (23) . Biochemical analyses of mutant PrP in selected ill founder animals ( Fig.  3 ) revealed the expression level to be equal to or lower than that in the brains of Tg-(SHaPrP) mice, again militating against the explanation of overexpression. Thus, similar to the KH3 II mutation, expression of the AV3 mutation caused a neurodegeneration in mice.
Histopathological examination of brains from ill Tg[SHaPrP(KH3 II) H ] mice revealed some neuropathological changes that were similar to those found in scrapie caused by inoculation of animals with prions. These changes included focal vacuolar degeneration of the gray matter neuropil (most pronounced in the hippocampus and piriform cortex; Fig. 2D ) and an associated astrocytic gliosis (Fig. 2E) 
The A117V mutation is in human PrP, and the data for this mutant derive from analysis in vitro (Fig. 4) or from human brain tissue (Fig. 6B ) (26) . The data for the other mutants derive from analysis of transgenic mice presented in this paper (Figs. 1 to 3 ). The topology of PrP in the brains of these transgenic mice was examined next. For these studies, brains were removed from animals, and intact microsomal membranes, containing PrP among other proteins, were prepared. These intact vesicles were then subjected to protease digestion, and the accessibility of PrP to protease was assessed by immunoblotting. Generation of a proteolytic fragment encompassing the COOH-terminus of PrP argues that these molecules are in the Ctm PrP orientation, whereas full protection from protease digestion indicates that the PrP is in the sec PrP orientation. Analysis of the proteolytic fragments was simplified by the removal, just before SDSpolyacrylamide gel electrophoresis (PAGE), of the highly heterogeneous carbohydrate trees with the enzyme PNGase F. This removal allowed us to look for the 18-kD COOH-terminal fragment characteristic of the Ctm PrP form, without the complications of heterogeneous electrophoretic migration of variably glycosylated PrP molecules. To ensure that vesicle integrity was maintained during the proteolysis reaction, we also evaluated the accessibility to protease of GRP94, an ER lumenal protein (24) .
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Only the Tg[SHaPrP(KH3 II) H ] and Tg[MH2MPrP(AV3)] brain samples contained PrP molecules spanning the membrane, which, after protease digestion in the absence of detergent, produced an 18-kD fragment (Fig. 3A) . This fragment produced by protease digestion was determined to be a COOH-terminal fragment of PrP on the basis of its detection with the 13A5 mAb and its observed slower migration on SDS-PAGE as a heterogeneous set of bands if polysaccharides were not removed from PrP before analysis (18 -+ + --+ ] mouse were prepared in PBS containing 1% NP-40 and 1% deoxycholate. The samples were either left untreated (odd numbered lanes) or digested with PK (100 g/ml) for 60 min at 37°(even numbered lanes) as described previously (45) . After termination of the PK reaction with PMSF, samples were analyzed by immunoblotting with the 13A5 mAb.
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Level of expression modulates Ctm PrP and disease. That the percentage of PrP molecules found in the Ctm PrP topology in vivo was consistently lower than that found in vitro (compare Fig. 1 with Fig. 3 (18) . These data further support the notion that Ctm PrP overexpression, and not the accumulation of protease-resistant PrP Sc , causes the neurodegeneration observed in transgenic mice expressing the KH3 II and AV3 mutations.
Ctm PrP and human neurodegenerative disease. Given that the distribution of newly synthesized PrP between transmembrane and secretory topologic forms is readily manipulated with mutations, we reasoned that there may exist in nature human mutations with similar, but less severe, effects on PrP topology. Such mutations would be likely to cause disease on a more delayed time scale, allowing them to be passed on to the next generation, and would be likely to have a less extreme skew in favor of Ctm PrP, when analyzed in cell-free systems. A PrP mutation causing GSS, in which there is an alanine (A) to valine (V) substitution at position 117 (A117V) (26) , was a likely candidate for several reasons. First, this mutation lies in the hydrophobic domain (TM1) that is crucial to the biogenesis of the transmembrane forms of PrP (12) . Second, the pathological findings in these cases of GSS (26) appear to share some features with mice that become ill because of Ctm PrP overexpression. Third, the biochemical examination of brain tissue from these cases of GSS has revealed little, if any, proteaseresistant PrP (27, 28) . These observations raised the possibility that a mechanism other than PrP Sc accumulation was involved in the pathogenesis of these cases of GSS.
To explore the mechanism by which the A117V mutation may cause disease, we compared the biogenesis in a cell-free system of this mutant PrP with its wild-type counterpart (both of which contained a valine at the polymorphic position 129). Upon examination of the GSS mutant PrP molecule [HuPrP(A117V)], we noticed that it consistently contained higher amounts of the transmembrane forms of PrP than did wild-type HuPrP (Fig. 4A) . Quantitative analysis of multiple independent translocation reactions (Fig. 4B ) demonstrated that the A117V mutation favored the synthesis of both Ctm PrP and Ntm PrP, with a concordant decrease of the sec PrP form. Thus, a mutation of PrP in the STE-TM1 region that is associated with human disease showed a relative preference for synthesis of the transmembrane forms of PrP upon expression in cell-free translation systems, consistent with the hypothesis that a transmembrane form of PrP could play a role in GSS.
To explore this idea further, we examined brain tissue from a GSS patient to determine whether in vivo, increased levels of transmembrane forms of PrP could be detected. Unfortunately, assay of protein topology in human brain is problematic because fresh tissue suitable for subcellular fractionation is not readily available. Moreover, frozen specimens do not maintain adequate subcellular architecture, posing yet another obstacle to isolation of intact intracellular membranes that would be suitable for topologic studies. To overcome these obstacles, we developed an alternate assay to distinguish 
www.sciencemag.org ⅐ SCIENCE ⅐ VOL. 279 ⅐ 6 FEBRUARY 1998 the different topological forms of PrP. We sought to exploit differences in the native conformations that would be expected of the different topologic forms of PrP. Such differences in conformation may be maintained in extracts from frozen brain and would be lost completely only upon denaturation. Differences in tertiary structure are often reflected in the relative accessibility of certain domains of a protein to macromolecular probes such as antibodies or proteases (29) . Indeed, an extreme example of this property is the differential sensitivity to PK of PrP C and PrP Sc , with the latter being highly resistant to digestion (16) . To determine whether a similar assay based on differential protease resistance could be used to distinguish the different topological forms of PrP, we digested cellfree translation products of PrP with PK under various conditions (Fig. 5A) . One or more nondenaturing detergents were included to solubilize membranes and allow the PK access to all of the PrP molecules in the reaction. We found that although harsh digestion at increased concentrations of PK (at Ͼ500 g/ml) or increased temperature (37°C) could digest completely all topological forms of PrP [but not PrP Sc (16) ], a subset of PrP was only partially digested under the milder conditions of PK (250 g/ml) and 0°C (Fig. 5A) . The fragment generated under these conditions comigrated on SDS-PAGE with the protected COOH-terminal domain generated in the standard topology assay.
Digestion of each of the topological mutants of PrP under the same conditions revealed that the generation of the protease-resistant fragment correlated well with the amount of Ctm PrP formed: Mutations that increased the relative amount of PrP in this form (A117V, KH3 II, and AV3) resulted in increased generation of the PK-resistant fragment, whereas mutations that abolished synthesis of this form (⌬STE and G123P) did not yield a PKresistant fragment (18) . As expected, all of the topological forms were completely digested by the harsher treatment under which PrP Sc is able to survive. Thus, at least in the cell-free system, these conditions were able to distinguish sec PrP and Ntm PrP from Ctm PrP, which could be further distinguished from PrP Sc (Fig. 5B) . To confirm that we could distinguish Ctm PrP from both sec PrP and PrP Sc in frozen brain tissue samples, we performed the assay on samples from transgenic mice in which the distribution of PrP among the topologic forms had previously been established. Frozen brain tissue from Tg-(SHaPrP), Tg[SHaPrP(KH3 II) L ], and Tg[SHaPrP(KH3 II) H ] mice was analyzed and compared with products of the standard topology assay performed with intact membranes. We further included as a marker the PrP Sc fragment generated from PK digestion of scrapie-infected hamster brain homogenate. We found that, similar to the results of the standard topology assay, the conformational assay generated a protease-protected fragment only in the Tg[SHaPrP(KH3 II) H ] sample (Fig. 6A) . Thus, the presence of this COOH-terminal fragment, generated under the mild but not under the harsh digestion conditions, appeared to be diagnostic for the presence of Ctm PrP. With the ability to analyze frozen brain tissue for the presence of Ctm PrP (distinguished from either PrP C , sec PrP, or PrP Sc ), we were able to ask whether GSS caused by the A117V mutation was due to increased levels of Ctm PrP. Frozen brain tissue from a neurologically normal patient and a GSS patient, taken at autopsy, was analyzed for the presence of Ctm PrP and PrP Sc with the appropriate assays. We found comparable levels of PrP in both normal and GSS human brain (Fig. 6B) . However, the GSS brain contained increased levels of Ctm PrP compared with the normal control (Fig.  6B) . By contrast, neither brain had detectable protease-resistant PrP Sc under conditions at which it was readily found in tissue from a sporadic CJD patient (Fig. 6B) . These results were independently confirmed by analysis of multiple samples of tissue from the same patient and also with brain tissue from a second patient carrying the same mutation. The lack of accumulation of protease-resistant PrP Sc was also independently confirmed for the second patient (28) . Thus, consistent with observations in vitro, the A117V mutation resulted in increased generation of Ctm PrP in vivo, suggesting that Ctm PrP accumulation is likely to be the cause of at least some of the neuropathological changes seen in these cases of GSS.
A new paradigm for PrP-induced neurodegeneration. Our studies were motivated by the desire to determine the role in prion diseases played by a transmembrane form of PrP that was first identified through the use of cell-free translation-translocation systems (10) . The hypothesis that a specific topologic form of PrP, namely Ctm PrP, is involved in the development of neurodegeneration is supported in several ways (summarized in Table 1 ). First, two independent mutations of PrP (KH3 II and AV3), which were initially identified by their ability to favor markedly the synthesis of (8, 27, 31) . Finally, it does not appear that the disease observed in this study is due to nonspecific accumulation of misfolded or aggregated PrP molecules. This conclusion is supported by the observation of nearly all of the Ctm PrP being located in a post-ER compartment, a lack of excessive accumulation of PrP (that is, no plaques or other localized deposition of PrP), and a lack of neuropathology characteristic of a storagetype disorder (32) . Together, these data support the hypothesis that expression of Ctm PrP may be involved in the pathologic process occurring in at least a subset of heritable prion diseases.
At present, the data in this study are suggestive of at least three distinct steps in the pathogenesis of Ctm PrP-associated neurodegenerative disease (Fig. 7) . The first step is preferential synthesis of Ctm PrP over other topological forms at the ER membrane. Second, newly synthesized Ctm PrP, which may normally be degraded rapidly, exits from the ER. Finally, in a post-ER compartment, Ctm PrP is proposed to serve an as yet unknown function to cause, directly or indirectly, neurodegeneration.
There are three lines of evidence for the first step. First, PrP can be made in more than one topological form in cellfree translation systems [(10-12) , and this study]. Second, Ctm PrP has now been detected in vivo (Fig. 3A) . Finally, PrP topology is dependent on both the amino acid sequence [(12) , and this study] and trans-acting factors in the cytosol (13) and in the ER membrane (18) . Thus, not only is PrP able to be made in multiple topological forms, but this step appears to be regulated in a complex manner. One prediction of this hypothesis is that, just as mutations in cis are able to affect both PrP topology and development of disease, loss or inactivation of specific trans-acting factors might also alter PrP topology in favor of Ctm PrP and potentiate development of neurodegeneration.
Once synthesized at the ER,
Ctm
PrP is thought to exit to a post-ER compartment on the basis of the acquisition of resistance to digestion by endo H (Fig. 3B) . We postulate that although exit from the ER can occur in some instances,
PrP may normally be degraded before exit, a fate observed for some posttranslationally regulated proteins (33) . This degradation may explain why the expression of any given PrP construct at the ER in the cell-free system results in a higher percentage of transmembrane PrP chains than were detectable for that construct in brain at steady state. Table 1 ). (B) Analysis of human tissue samples for Ctm PrP. Five percent homogenates were prepared from frozen brain tissue removed at autopsy from a neurologically normal individual and a GSS case containing the A117V mutation. Portions were digested with PK under either mild (M) or harsh (H) conditions as described in Fig. 5B (46) , and the samples were normalized for individual variations in starting PrP levels before analysis by SDS-PAGE and protein immunoblotting with the 3F4 mAb. The left panel shows a portion of each sample before digestion with PK and the right panel after the digestions. As a marker for human PrP Sc , homogenate from the brain of a sporadic CJD (lane 5) case was digested under the harsh conditions, and a portion was analyzed in parallel. 
